Sign in
ONTX Stock Price, Chart, Stats & News
Onconova Therapeutics, Inc.
Save
536.22M
Market cap
–
Current P/E
–
Forward P/E
ONTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | -1403773.30% |
Pretax margin | -1253721.31% |
Net margin | -1019761.69% |
Effective tax rate | – |
ROA | -31.74% |
ROE | -123.60% |
D/E | – |
Interest coverage ratio | – |
ONTX valuation
P/E | – |
P/S | 53.98x |
P/B | 0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | -0.01x |
EV multiple | -1.63x |
About
Onconova Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, focused on identifying and advancing innovative therapeutic solutions for oncological diseases. The company's pipeline currently highlights two primary drug candidates undergoing clinical trials: 1. Narazaciclib (ON 123300): This is a multi-targeted kinase inhibitor being evaluated in Phase I studies.
Similar securities
Based on sector and market capitalization
Report issue